← Companies|Synthorx (Sanofi)
Sy

Synthorx (Sanofi)

La Jolla CAFounded 201450 employees
Private CapbiotechAcquiredOncology
Platform: IL-2 variant
Market Cap
N/A
All Drugs
3
Clinical Trials
8
Failed / Terminated
2
FDA Approved
1
Drug Pipeline (3 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
DoxasertibSYN-8630Preclinical1RadioligandAuroraAIL-23iUCTTR Amyloidosis
DoxarasimodSYN-513Phase 34Fusion ProteinGLP-1RPLK4iCTCLCSU
ZanufotisoranSYN-6569Approved3ASOBETTYK2iCKDADPKD
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (8)
2025-08-09
Zanufotisoran Ph3 Readout
CKD
Past
2025-10-18
Doxarasimod Ph3 Readout
CTCL
Past
2025-12-11
Zanufotisoran Ph3 Readout
ADPKD
Past
2026-07-21
Doxarasimod Ph3 Readout
CSU
Ph3 Readout
2027-05-23
Doxarasimod Ph3 Readout
MDD
Ph3 Readout
2028-05-03
Doxasertib Interim
UC
Interim
2029-12-07
Zanufotisoran Ph3 Readout
CKD
Ph3 Readout
2030-12-13
Doxarasimod Ph3 Readout
MDD
Ph3 Readout